The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting , to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev. | March 30, 2023
The FDA approved efanesoctocog alfa, a once-weekly treatment for children and adults with hemophilia A.The approval applies to use of the factor VIII replacement therapy as routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment for control of bleeds, and for perioperative management of bleeding. Efanesoctocog alfa (Altuviiio; Bioverativ Therapeutics, Sanofi) is not
PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas - read this article along with other careers information, tips and advice on BioSpace